Magic Empire Glbの空売り状況は、投資家がMagic Empire Glbの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Magic Empire Glb (NASDAQ:MEGL) 株価情報, 空売り情報

Magic Empire Global

Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.

Magic Empire Global Limited - Class A Ordinary Shares

Magic Empire Global Ltd

Earnings

News

ADTN

CORRECTION: Adtran Q1 Adj. EPS $0.03 Beats $(0.03) Estimate, Sales $247.74M Beat $245.15M Estimate

Citigroup analyst Kyle Menges maintains Regal Rexnord (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRX#NYSE">RRX</a>) with a Buy and raises the price target from $110 to $145.

Price Target

Analyst Ratings

Citigroup Maintains Buy on Regal Rexnord, Raises Price Target to $145

US Foods Holding Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>) shares are trading higher after the company <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45280354/us-foods-reports-first-quarter-fiscal-year-2025-earnings" rel="noreferrer noopener">reported first-quarter results.</a>
The company reported adjusted earnings per share of 68 cents, missing the analyst consensus estimate of 69 cents. Quarterly sales of $9.35 billion (up 4.5% year over year) missed the Street view of $9.38 billion.
Sysco reported a 1.1% rise in total case volume, including a 2.5% increase from independent restaurants, while gross profit grew 8% to $1.6 billion.
Net income surged 40.2% to $115 million, and adjusted EBITDA rose 9.3% to $389 million. Adjusted EBITDA margin was 4.2%, an increase of 18 basis points compared to the prior year.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45294069/crude-oil-gains-over-2-us-foods-posts-downbeat-earnings" rel="noreferrer noopener">Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings</a>
CEO Dave Flitman noted how adjusted diluted EPS increased 26% &#8220;despite the challenging operating environment and weather-related headwinds.&#8221;
Total case volume rose 1.1% year-over-year, led by a 2.5% gain in independent restaurant volume.
Healthcare and hospitality volumes grew 6.1% and 3.6%, respectively, while chain volume declined 4.3%.
Adjusted Gross profit was $1.6 billion, an increase of 5.1% from the prior year. Adjusted Gross profit as a percentage of net sales was 17.3%.
On May 7, the company authorized a new share repurchase program of up to $1 billion.
Outlook: US Foods reaffirmed its fiscal 2025 adjusted EPS guidance of $3.69 to $3.88, compared to the $3.79 analyst estimate.
The company also maintained its fiscal 2025 sales outlook of $39.39 billion to $40.15 billion, compared with the $39.75 billion estimate.
Price Action: US Foods shares are trading higher by 4.51% to $72.29 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45293256/disney-stock-resilient-in-uncertain-economy-as-raised-guidance-signals-confidence" target="_blank" rel="noreferrer noopener">Disney Stock &#8216;Resilient&#8217; In Uncertain Economy As Raised Guidance Signals Confidence</a></li>
</ul>
Image: Shutterstock

Equities

Guidance

Buybacks

Markets

Movers

General

USFD

US Foods Dishes Out 40% Net Income Gain, Readies $1 Billion Buyback

Citigroup analyst Steven Enders maintains Dayforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAY#NYSE">DAY</a>) with a Buy and raises the price target from $68 to $70.

Citigroup Maintains Buy on Dayforce, Raises Price Target to $70

Citigroup analyst Atif Malik maintains Entegris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>) with a Buy and lowers the price target from $125 to $102.

ENTG

Citigroup Maintains Buy on Entegris, Lowers Price Target to $102

<a href="https://www.bloomberg.com/news/articles/2025-05-08/shell-s-lng-canada-plans-first-exports-as-soon-as-late-june" title="https://www.bloomberg.com/news/articles/2025-05-08/shell-s-lng-canada-plans-first-exports-as-soon-as-late-june">https://www.bloomberg.com/news/articles/2025-05-08/shell-s-lng-canada-plans-first-exports-as-soon-as-late-june</a>

Commodities

SHEL

Bloomberg: 'Shell's LNG Canada Plans First Exports as Soon as Late June'

Citigroup analyst Andrew Kaplowitz maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Buy and raises the price target from $283 to $327.

Citigroup Maintains Buy on Rockwell Automation, Raises Price Target to $327

WIIM

SEDG

SolarEdge Technologies shares are trading higher. The company recently reported better-than-expected Q1 financial results and issued Q2 sales guidance above estimates.

Citigroup analyst Michael Rollins maintains Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) with a Buy and raises the price target from $330 to $355.

Citigroup Maintains Buy on Cencora, Raises Price Target to $355

Germany's <a href="https://www.benzinga.com/topic/germany-cannabis">cannabis landscape</a> continues evolving at a rapid pace. From extensive pharmacy access to a surge in cultivation associations, the country's dual-track model—medical and non-commercial adult use—has turned it into one of the most closely watched cannabis markets in the world.
Still, many in the industry argue that restrictive EU regulations are preventing Germany from reaching its full potential.
<h3 class="wp-block-heading">1 In 7 Pharmacies Now Dispenses Medical Cannabis</h3>
As reported by <a href="https://internationalcbc.com/more-than-1-out-of-every-7-german-pharmacies-offers-medical-cannabis/?utm_source=ICBC+Combined+List+Newsletter+and+Outreach&amp;utm_campaign=7599cd320e-EMAIL_CAMPAIGN_2025_05_05_06_44&amp;utm_medium=email&amp;utm_term=0_-7599cd320e-23726375">ICBC</a>, roughly 2,500 of Germany's 17,000 pharmacies now offer medical cannabis products—a dramatic expansion since legal access began in 2017. Patients can also order cannabis online with a private prescription and have it delivered directly to their homes.
According to the German Cannabis Business Association (BvCW), the country's legal medical cannabis revenue is now estimated at around half a billion euros annually.
Yet that number only scratches the surface of the market's potential. At ICBC Berlin, economist Beau Whitney presented data showing flower and extract sales dominate the German market due to a ban on edibles and other product formats. For comparison, U.S. 4/20 sales were only 41% flower, with the rest divided between vapes, <a href="https://www.benzinga.com/markets/cannabis/25/05/45263739/they-turned-fruit-bouquets-into-a-500m-a-year-businessnow-theyre-selling-thc-heres-why">edibles</a>, <a href="https://www.benzinga.com/markets/cannabis/25/04/44929611/why-pre-rolls-are-cannabis-most-profitable-format-from-california-to-canada">pre-rolls</a> and topicals.
The takeaway? Consumers who prefer smokeless options have limited legal choices in Germany, leaving the door open for the unregulated market.
<h3 class="wp-block-heading">Germany's Cultivation Associations Are Growing Fast</h3>
Meanwhile, the number of licensed cannabis cultivation associations continues to rise. As of early May, Germany had approved 211 of the 624 applications submitted nationwide since the member-based model went live in July 2024.
The associations—legal under EU health policy frameworks—allow registered members to collectively grow cannabis for personal use. Though not commercial in nature, they offer a legal alternative for adults seeking safe, regulated cannabis outside the pharmacy system.
For perspective, Malta—another EU member state with a similar model—has issued 19 permits for its 570,000 residents. Applying Malta's ratio to Germany's population of 84 million implies that over 2,800 associations could eventually be formed.
Still, much remains in flux. Only 25 German applications have been formally rejected so far and many approved groups are still navigating the setup phase.
<h3 class="wp-block-heading">What's Next?</h3>
Germany is already Europe's largest cannabis market, and interest from international operators and policymakers shows no sign of slowing. But experts say broader legalization—including more product categories and commercial access—is essential to meet patient demand and curb illicit activity.
As the BvCW notes, &#8220;the industry's revenue is now estimated at around half a billion euros"—but with edibles, national retail and broader exports still off-limits, the true ceiling remains far higher.
<h3 class="wp-block-heading">Stocks To Watch</h3>
Germany's expanding cannabis market has attracted significant investment from major publicly traded companies. Here are some key players:
<ul>
<li>Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>): Tilray operates a GMP-certified cultivation facility in Neumünster and has recently expanded its medical cannabis offerings in Germany, including new extract formulations and high-THC flower strains under the Tilray Craft brand.</li>
<li>Aurora Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>): Aurora launched its first domestically grown medical cannabis brand, IndiMed, cultivated at its EU-GMP facility in Leuna. This move positions Aurora as one of the few companies with local production capabilities in Germany.</li>
<li>Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>): Canopy Growth has introduced its Tweed brand to the German medical cannabis market, expanding its product lineup with new strains through strategic partnerships with EU-based cultivators.</li>
<li>Curaleaf Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>): Curaleaf has taken a majority stake in Germany&#8217;s Four 20 Pharma, enhancing its footprint in the European market and aiming to leverage Four 20 Pharma&#8217;s distribution network.</li>
<li>High Tide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>): High Tide initially planned to enter the German medical cannabis market through the acquisition of Purecan GmbH. However, the company is currently reevaluating this strategy and exploring alternative arrangements to establish a presence in Germany.</li>
</ul>
Photo: Shutterstock

Cannabis

Eurozone

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

HITI

TLRY

Germany's Cannabis Industry Hits 500 Million Euros: 2,500 Pharmacies Now Dispense, 211 Grow Clubs Approved

Ark Invest CEO and Founder Cathie Wood is no stranger to loving companies that are founded and/or run by Elon Musk, with <a href="https://www.benzinga.com/24/12/42486618/heres-how-much-1000-invested-in-tesla-stock-today-will-be-worth-if-cathie-woods-price-prediction-comes-true-in-2029">her early bets </a>on Tesla, SpaceX and others.
The Ark Venture Fund, which <a href="https://www.benzinga.com/news/22/11/29524537/cathie-wood-invested-in-musks-twitter-takeover-how-you-can-get-a-stake-for-500">offers access </a>to private companies, added to its stake in a Musk company during the first quarter. This is in addition to SpaceX already being the fund&#8217;s top holding.
What Happened: During the first quarter, the Ark Venture Fund reinvested in X Corp, the company previously known as Twitter. That new stake converted into a position in xAI, Musk's artificial intelligence company, thanks to a<a href="https://www.benzinga.com/tech/25/03/44549314/elon-musk-acquires-his-own-social-media-platform-x-through-xai-in-33-billion-deal-says-combined-entity-now-worth-80-billion"> merger of the two companies.</a>
The merger valued xAI at $80 billion and X at $33 billion to create the combined xAI Holdings Corp company.
Ark's quarter summary <a href="https://www.ark-funds.com/articles/venture-fund/ark-venture-q1-2025-update">letter </a>said the combined company will integrate the "cutting-edge foundational models" of xAI with X's user base of more than 600 million people. The letter said the merger could "unlock a platform that blends real-time communication with AI-enhanced discovery, truth-seeking, and personalized knowledge delivery."
"We believe this merger will be a significant catalyst for consumer AI adoption and foundational model monetization," the letter said.
Here are the fund's top 10 <a href="https://www.ark-funds.com/funds/arkvx?utm_source=adwords&amp;utm_medium=ppc&amp;hsa_acc=2895577906&amp;hsa_cam=22423858049&amp;hsa_src=x&amp;hsa_net=adwords&amp;hsa_ver=3&amp;gad_source=1&amp;gad_campaignid=22420004586&amp;gbraid=0AAAAADoxXfLelVrScBMGodSi-ZYIxu_IE&amp;gclid=Cj0KCQjwrPHABhCIARIsAFW2XBMOnMDrFcbeL01AQJvT4M3Ii56kvRlmTf8Mr1iE4ejZk1soqgaYnMYaAnqGEALw_wcB">holdings </a>as of April 30, with the percent of the fund's assets:
<ol>
<li>SpaceX: 14.6%</li>
<li>OpenAI: 7.5%</li>
<li>X.AI: 6.3%</li>
<li>Hammerspace: 3.6%</li>
<li>Anthropic: 3.5%</li>
<li>Lambda Labs: 3.5%</li>
<li>Blockdaemon: 3.3%</li>
<li>Epic Games: 2.6%</li>
<li>Shield AI: 2.5%</li>
<li>Radiant Industries: 2.4%</li>
</ol>
SpaceX and xAI, two Musk-related companies are two of the top three holdings, while OpenAI, which Musk was also involved with previously, ranks second.
Together, the stakes in SpaceX and xAI represent 20.9% of the fund's assets.
Read Also: <a href="https://www.benzinga.com/top-stories/24/08/40423891/buffett-musk-wood-cuban-or-ackman-who-do-investors-trust-most-with-life-savings-poll-shows-it-isnt-e">Buffett, Musk, Wood, Cuban Or Ackman: Who Do Investors Trust Most With Life Savings? Poll Shows It Isn&#8217;t Even Close</a>
Other Investments: The Ark Venture Fund made several investments in sectors it believes in for the long-term as part of its strategy to find innovative companies.
"Amid the volatility and uncertainty dominating the opening months of the year, our conviction in the opportunity to invest in disruptive innovation remains strong," Ark said.
In the Robotics sector, Ark Venture Fund invested in Apptronik and Kodiak Robotics. The company said Apptronik is addressing global labor shortages and working toward a future where robots and humans can work together. Kodiak Robotics is an <a href="https://www.benzinga.com/markets/equities/25/04/44809515/george-soros-cathie-wood-backed-autonomous-trucking-firm-kodiak-robotics-set-to-go-public-via-spac-merger-to-tap-4-trillion-market">autonomous trucking company </a>founded by Don Burnette, who was a co-founder of Uber's self-driving truck division.
"As autonomous logistics scales, Kodiak is well positioned to lead in operational efficiency and safety."
The Ark Venture Fund also made its first investment in the nuclear energy space with an investment in Radiant Nuclear. The letter says Radiant Nuclear was founded by former SpaceX engineers.
Semiconductor company Groq and cloud infrastructure company Lambda Labs were new investments by the fund for the next-generation internet sector.
"With strong momentum in both government and enterprise sectors, Groq is emerging as a core player in real-time AI computer infrastructure."
Other investments by Ark in the quarter also include fintech Revolut and Generate:Biomedicines and Lila Sciences in the AI sciences space.
"We are energized by what's ahead in 2025 and encouraged by the growth and engagement of our investor community."
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/mutual-funds/24/04/38213342/cathie-wood-ark-invest-announce-stake-in-openai-heres-how-you-can-get-exposure-to-chatgpt-pa">Cathie Wood, Ark Invest Announce Stake In OpenAI: Here&#8217;s How You Can Get Exposure To ChatGPT Parent, X (Twitter), SpaceX, Discord, Epic Games</a></li>
</ul>
Photo: Shutterstock

Financing

Tech

After SpaceX, Cathie Wood Bets Big on Elon Musk's xAI

Citigroup analyst Andrew Kaplowitz maintains Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) with a Buy and raises the price target from $119 to $127.

Citigroup Maintains Buy on Emerson Electric, Raises Price Target to $127

Citigroup analyst Andrew Gardiner maintains ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Buy and lowers the price target from $200 to $170.

Citigroup Maintains Buy on ARM Holdings, Lowers Price Target to $170

Citigroup analyst Ygal Arounian maintains Redfin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) with a Neutral and raises the price target from $7.3 to $9.2.

RDFN

Citigroup Maintains Neutral on Redfin, Raises Price Target to $9.2

Citigroup analyst Tyler Radke maintains Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) with a Neutral and raises the price target from $110 to $115.

PLTR

Citigroup Maintains Neutral on Palantir Technologies, Raises Price Target to $115

Pagaya Technologies shares are trading higher after the company on Wednesday reported better-than-expected Q1 financial results, issued Q2 sales guidance above estimates, and raised its FY25 sales guidance

Citigroup analyst Asiya Merchant maintains CDW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDW#NASDAQ">CDW</a>) with a Neutral and raises the price target from $160 to $180.

Citigroup Maintains Neutral on CDW, Raises Price Target to $180

BMBL

Bumble shares are trading higher following mixed Q1 financial results.

Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) will release its quarterly earnings report on Friday, 2025-05-09. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Ocugen to report an earnings per share (EPS) of $-0.06.
Investors in Ocugen are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings History Snapshot</h3>
The company's EPS missed by $0.00 in the last quarter, leading to a 9.96% increase in the share price on the following day.
Here's a look at Ocugen's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.05</td>
<td>-0.05</td>
<td>-0.05</td>
<td>-0.06</td>
<td>-0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.05</td>
<td>-0.05</td>
<td>-0.04</td>
<td>-0.05</td>
<td>-0.04</td>
</tr>
<tr>
<td>Price Change %</td>
<td>10.0%</td>
<td>-9.0%</td>
<td>-2.0%</td>
<td>15.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746730915_0.png" alt="eps graph" />
<h3>Ocugen Share Price Analysis</h3>
Shares of Ocugen were trading at $0.6621 as of May 07. Over the last 52-week period, shares are down 56.46%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Insights on Ocugen</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Ocugen.
The consensus rating for Ocugen is Buy, derived from 4 analyst ratings. An average one-year price target of $7.25 implies a potential 995.0% upside.
<h3>Peer Ratings Overview</h3>
The analysis below examines the analyst ratings and average 1-year price targets of and Y-mAbs Therapeutics, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<h3>Peer Analysis Summary</h3>
Within the peer analysis summary, vital metrics for and Y-mAbs Therapeutics are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y-mAbs Therapeutics</td>
<td>Buy</td>
<td>13.41%</td>
<td>$18.65M</td>
<td>-7.36%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Ocugen ranks at the bottom for Revenue Growth and Gross Profit among its peers. It is also at the bottom for Return on Equity. The Consensus rating for Ocugen is not provided for comparison.
<h3>Delving into Ocugen's Background</h3>
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
<h3>Breaking Down Ocugen's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Ocugen's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -45.78%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Ocugen's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -1816.75%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Ocugen's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -39.51%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Ocugen's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -19.23%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Ocugen's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.1, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<a href="https://www.benzinga.com/quote/OCGN/earnings">To track all earnings releases for Ocugen visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

OCGN

A Look at Ocugen's Upcoming Earnings Report

UBS analyst Kevin Caliendo maintains American Well (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) with a Neutral and lowers the price target from $12 to $9.

AMWL

UBS Maintains Neutral on American Well, Lowers Price Target to $9

Press Releases

Magic Empire Global Limited Announces Receipt of Nasdaq Notification of additional 180 calendar day period to regain compliance of minimum bid price requirement

Magic Empire Global Limited Announces First Half 2024 Unaudited Financial Results

Magic Empire Global Limited announces that the bid price deficiency concern raised by Nasdaq has been successfully resolved

MEGL

AMTD IDEA Group American Depositary Shares, each representing six (6) Class A Ordinary Shares

Comments

Magic Empire Glb

空売り

Magic Empire Glb (NASDAQ:MEGL) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル